RxDoctor Payments Data

Miriam Brown, MD

Ophthalmology · Moorestown, NJNPI 1225035306

Payments from drug & device makers

$1,967in general payments, 2019–2025

Across 92 payments — averaging $21.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$432
  • Tarsus Pharmaceuticals, Inc.$306
  • Dompe US, Inc.$246
  • Sun Pharmaceutical Industries Inc.$226
  • Sight Sciences, Inc.$147
  • Oyster Point Pharma, Inc.$110
  • plus $501 from 13 others

What the payments were for

  • Food & beverage$1,967100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,967 in reported general payments places this provider in the 55th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$372,711
Medicare patients
1,445
Services billed
3,863

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine184$209,241
LumiganBimatoprost296$168,892
Cyclosporine208$143,734
XiidraLifitegrast80$90,849
Brimonidine Tartrate386$79,236
Alphagan PBrimonidine Tartrate69$26,947
MieboPerfluorohexyloctane/Pf20$22,119
SimbrinzaBrinzolamide/Brimonidine Tart46$20,671
TyrvayaVarenicline Tartrate18$20,255
XdemvyLotilaner11$20,028
CequaCyclosporine15$19,770
Latanoprost1,014$14,229
Travoprost59$10,445
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol46$10,414
RhopressaNetarsudil Mesylate11$8,630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$432$411,177566 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$82$112,967100 claims
AlconSimbrinza$44$20,67146 claims
Oyster Point Pharma, Inc.Tyrvaya$110$20,25518 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$306$20,02811 claims
Sun Pharmaceutical Industries Inc.Cequa$226$19,77015 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$56$15,32231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Moorestown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →